

John Molot, MD, a leading medical and scientific advisor, delivered a landmark presentation that provides a scientific label for Multiple Chemical Sensitivity (MCS) and supports it with a concrete biological framework. His primary goal was to demonstrate that MCS is not a psychological condition, but a predictable physiological reaction grounded in evolutionary medicine and modern toxicology. By using the Bradford Hill criteria - a gold-standard scientific framework for proving cause and effect - Dr. Molot argued that we can finally move past the harmful psychiatric labelling that leads to incorrect treatments like behavioural therapy and instead focus on the true biological drivers of the condition.

At the center of his argument is the concept of evolutionary mismatch. Dr. Molot explained that for billions of years, living organisms developed sophisticated cellular defence systems to detect and avoid environmental toxins. These ancient systems rely on specialized molecular sensors called TRP receptors, which act like biological "smoke alarms." In our modern world, however, humans are exposed to a relentless cocktail of synthetic chemicals from "womb to tomb." For people with MCS, these ancient smoke alarms have become hypersensitive. This is not a malfunction in the mind, but a recalibration of the body's physical defence setpoints. When these receptors are constantly bombarded by indoor pollutants and scents, they enter a state of "allostatic load," where the body is under such continuous strain that its thresholds for reaction drop significantly, causing the nervous and respiratory systems to overreact to even trace amounts of chemicals.

Dr. Molot directly challenged the outdated toxicological belief that "the dose makes the poison." While classical toxicology focuses on high-dose exposures, Dr. Molot showed that MCS is best understood through systems biology and the toxic potential of mixtures. He explained that MCS patients often have less effective detoxification systems, which leads to oxidative stress and tissue damage. This damage further sensitizes the TRP receptors, creating a feedback loop where the body becomes increasingly reactive. He highlighted that there are now 21 case-control studies and 9 brain imaging studies confirming that the central nervous systems of people with MCS process chemical signals differently than unaffected individuals. These are measurable, physical changes in the body that cannot be ignored or dismissed as "subjective."

To provide a roadmap for clinical understanding, Dr. Molot introduced the Adverse Outcome Pathway for MCS. This model links a specific stressor, like common household chemicals, to a molecular initiating event (the binding of those chemicals to TRP receptors). This triggers a sequence of key biological events, including the sensitization of sensory nerves and the release of inflammatory messengers. The final outcome is the medically observable MCS phenotype, characterized by multi-organ symptoms and functional impairment. Dr. Molot proved that the link between chemical exposure and MCS symptoms is a coherent, mechanistic pathway rather than a random correlation.

Ultimately, Dr. Molot's presentation served as a powerful validation of the MCS mechanism. He emphasized that the rising prevalence of the condition in Canada is a signal that our environmental reality is overwhelming our biological capacity to adapt. He provided the scientific community with a clear mandate to start addressing the environmental triggers and

physiological sensitization at the root of the disease. This shift in perspective is vital for ensuring that patients receive appropriate environmental accommodations and medical care based on science rather than stigma.

References

- Aiyer K. The Great Oxidation Event: How Cyanobacteria Changed Life. American Society for Microbiology. February 18, 2022
- Amatori S. The Evolutionary Misfit: Evolution, Epigenetics, and the Rise of Non-Communicable Diseases. *Epigenomes*. 2025 Dec 13;9(4):51.
- Andersson L, Claesson AS, Dantoft TM, Skovbjerg S, Lind N, Nordin S. Chemosensory perception, symptoms and autonomic responses during chemical exposure in multiple chemical sensitivity. *Int Arch Occup Environ Health*. 2016 Jan;89(1):79-88.
- Bal-Price A, Meek MEB. Adverse outcome pathways: Application to enhance mechanistic understanding of neurotoxicity. *Pharmacol Ther*. 2017 Nov;179:84-95.
- Banuelos S, et al. Estimating the effect of reducing average annual ambient PM2.5 concentrations on allostatic load in children. *Environ Res*. 2026 Mar 1;292:123613.
- Bautista DM, et al. TRPA1 mediates the inflammatory actions of environmental irritants and proalgesic agents. *Cell*. 2006 Mar 24;124(6):1269-82.
- Becker RA, et al. Increasing Scientific Confidence in Adverse Outcome Pathways: Application of Tailored Bradford-Hill Considerations for Evaluating Weight of Evidence. *Regul Toxicol Pharmacol*. 2015 Aug;72(3):514-37.
- Bell IR, Baldwin CM, Schwartz GE. Sensitization studies in chemically intolerant individuals: implications for individual difference research. *Ann N Y Acad Sci*. 2001 Mar;933:38-47.
- Bessac BF, Jordt SE. Sensory detection and responses to toxic gases: mechanisms, health effects, and countermeasures. *Proc Am Thorac Soc*. 2010 July;7(4):269-77.
- Bloch D, et al. Basic concepts of mixture toxicity and relevance for risk evaluation and regulation. *Arch Toxicol*. 2023 Nov;97(11):3005-3017.
- Bjerregaard AA, et al. Heart rate variability is not associated with multiple chemical sensitivity in a cross-sectional population-based study - The Danish study of functional disorders. *J Psychosom Res*. 2025 Jan;188:111992.
- Caceres AI, et al. A sensory neuronal ion channel essential for airway inflammation and hyperreactivity in asthma. *Proc Natl Acad Sci U S A*. 2009 Jun 2;106(22):9099-104.
- Carrier G, et al. Multiple chemical sensitivity, an integrative approach to identifying the pathophysiological mechanisms. June 29, 2021;130355.
<https://www.inspq.qc.ca/en/publications/2730>
- Craig AD. How do you feel? Interoception: the sense of the physiological condition of the body. *Nat Rev Neurosci*. 2002;3(8):655-666.
- Del Casale A, et al. Multiple Chemical Sensitivity Syndrome: A Principal Component Analysis of Symptoms. *Int J Environ Res Public Health*. 2020 Sep;17(18):6551
- Final Report of the Task Force on Environmental Health. Government of Ontario, Ministry of Health and Long-Term Care; 2018

- Froghi S. New Insights on the Role of TRP Channels in Calcium Signalling and Immunomodulation: Review of Pathways and Implications for Clinical Practice. *Clin Rev Allergy Immunol*. 2021 Apr;60(2):271-292.
- Gibson et al. Perceived treatment efficacy for conventional and alternative therapies reported by persons with multiple chemical sensitivity. *Environ Health Perspect*. 2003 Sep;111(12):1498-504.
- Glette-Iversen I, et al. The concept of plausibility in a risk analysis context: Review and clarifications of defining ideas and interpretations. *Safety Sci*. 2022 Mar;147:105635
- Groh KJ, et al. Development and application of the adverse outcome pathway framework for understanding and predicting chronic toxicity: I. Challenges and research needs in ecotoxicology. *Chemosphere*. 2015 Feb;120:764-77.
- Hargitai R, et al. Chemical respiratory sensitization-Current status of mechanistic understanding, knowledge gaps and possible identification methods of sensitizers. *Front Toxicol*. 2024 Jul 29;6:1331803.
- Hill AB. The environment and disease: Association or causation? *Proceed Roy Soc Med*. 1965;58:295–300
- Jacques L. Multiple Chemical Sensitivity: A Clinical Perspective. *Brain Sci*. 2024 Dec 16;14(12):1261.
- Jadhakhan J, et al. Prevalence of medically unexplained symptoms in adults who are high users of healthcare services and magnitude of associated costs: a systematic review. *BMJ Open*. 2022 Oct 5;12(10):e059971.
- Julius D. TRP channels and pain. *Annu Rev Cell Dev Biol*. 2013;29:355-384.
- LeDoux JE. Emotion circuits in the brain. *Annu Rev Neurosci*. 2000;23:155-184.
- Lacour M, et al. Multiple Chemical Sensitivity Syndrome (MCS) – suggestions for an extension of the US MCS-case definition. *International Journal of Hygiene and Environmental Health*. 2005 May;208(3):141–51.
- Maia LJR, et al. Environmental contaminants and the HPA axis: Advances in adrenocortical hormone research in cetaceans. *Chemosphere*. 2025 Sep;385:144562.
- Martinez J and Eling T. Volatile Organic Chemicals Activate TRPA1 Receptor to Induce Sensory Pulmonary Irritation. *AOP*:196 April 29, 2023. https://aopwiki.org/aops/196#aop_title
- McEwen BS. Protective and damaging effects of stress mediators: central role of the brain. *Dialogues Clin Neurosci*. 2006;8(4):367-81.
- Meek ME, et al. Mode of action human relevance (species concordance) framework: Evolution of the Bradford Hill considerations and comparative analysis of weight of evidence. *J Appl Toxicol*. 2014 Jun;34(6):595-606
- Mittal M et al. Reactive oxygen species in inflammation and tissue injury. *Antioxidants & Redox Signaling*. 2014.
- Mizukoshi A, et al. In-situ Real-Time Monitoring of Volatile Organic Compound Exposure and Heart Rate Variability for Patients with Multiple Chemical Sensitivity. *Int J Environ Res Public Health*. 2015 Oct 5;12(10):12446-65.

- Molot J, et al. Multiple Chemical Sensitivity: It's time to catch up to the science. *Neurosci Biobehav Rev.* 2023 Aug;151:105227.
- Moulton PV, Yang W. Air pollution, oxidative stress, and Alzheimer's disease. *J Environ Public Health.* 2012;2012:472751.
- Moltzau Anderson J, Horn F. (Re-) Defining evolutionary medicine. *Ecol Evol.* 2020 Oct 1;10(20):10930-10936
- Natterson-Horowitz B, et al. The future of evolutionary medicine: sparking innovation in biomedicine and public health. *Front Sci.* 2023;1:997136.
- Nesse RM, et al. Evolution in health and medicine Sackler colloquium: Making evolutionary biology a basic science for medicine. *Proc Natl Acad Sci U S A.* 2010 Jan 26;107 Suppl 1(Suppl 1):1800-7.
- Palmiter RD. The parabrachial nucleus: CGRP neurons function as a general alarm. *Trends Neurosci.* 2018 May;41(5):280–93.
- Pande A, et al. Prenatal exposure to synthetic chemicals in relation to HPA axis activity: A systematic review of the epidemiological literature. *Sci Total Environ.* 2024 Dec 15;956:177300.
- Perales RB, et al. Does improving indoor air quality lessen symptoms associated with chemical intolerance? *Prim Health Care Res Dev.* 2022 Jan 12;23:e3.
- Pitron V, et al. Multiple chemical sensitivity: Catching up to what kind of science? *Environmental Health.* 2023;22(1):50.
- Ray PD, et al. Reactive oxygen species (ROS) homeostasis and redox regulation in cellular signaling. *Cell Signal.* 2012
- Rossi S, Pitidis A. Multiple Chemical Sensitivity: Review of the State of the Art in Epidemiology, Diagnosis, and Future Perspectives. *Journal of Occupational and Environmental Medicine.* 2018 Feb;60(2):138–46.
- Slikker W Jr, et al. Systems biology approaches for toxicology. *J Appl Toxicol.* 2007 May-Jun;27(3):201-17.
- Steinemann A. International prevalence of chemical sensitivity, co-prevalences with asthma and autism, and effects from fragranced consumer products. *Air Qual Atmos Health.* 2019;12(5):519-527.
- Steinemann A. National Prevalence and Effects of Multiple Chemical Sensitivities. *J Occup Environ Med.* 2018;60(3):e152-e156.
- Suzuki T, et al. Environmental pollutants and the immune response. *Nat Immunol.* 2020 Dec;21(12):1486-1495.
- Taboureau O, et al. Integrative systems toxicology to predict human biological systems affected by exposure to environmental chemicals. *Toxicol Appl Pharmacol.* 2020 Oct 15;405:115210.
- Talavera K, et al. Mammalian Transient Receptor Potential TRPA1 Channels: From Structure to Disease. *Physiol Rev.* 2020 Apr 1;100(2):725–803.

- Thomson EM. Air Pollution, Stress, and Allostatic Load: Linking Systemic and Central Nervous System Impacts. *J Alzheimers Dis*. 2019;69(3):597-614.
- Wang Y, et al. Large-scale forward genetics screening identifies *Trpa1* as a chemosensor for predator odor-evoked innate fear behaviors. *Nat Commun*. 2018 May 23;9(1):2041. .
- Weng H-J, et al. *Tmem100* Is a Regulator of TRPA1-TRPV1 Complex and Contributes to Persistent Pain. *Neuron*. 2015 Feb 18;85(4):833–46.
- World Health Organization. Noncommunicable diseases country profiles. 2018
- Zheng J. Molecular mechanism of TRP channels. *Compr Physiol*. 2013 Jan;3(1):221-42.